Amoroso A
Minerva Med. 1975 May 26;66(39):1904-13.
Verapamil was administered intravenously to 250 patients aged between 14 and 85, suffering from tachyarrhythmia of various type. The commonest heart conditions were hypertensive cardiopathy, acquired valvular defects, and ischaemic cardiopathy. The antiarrhythmia effectiveness of the treatment is shown by the excellent results obtained in sinus tachycardia, supraventricular paroxysmal tachycardia, high frequency atrial fibrillations and even in a patient with WPW syndrome and supraventricular paroxysmal tachycardia and in one of the 5 patients with ventricular tachycardia. Generally speaking, the treatment was continued orally in a dose of 240 mg per day, and it was possible to control the clinical situation with no side effects.
对250名年龄在14至85岁之间、患有各种类型快速心律失常的患者静脉注射维拉帕米。最常见的心脏疾病是高血压性心脏病、后天性瓣膜缺损和缺血性心脏病。窦性心动过速、室上性阵发性心动过速、高频心房颤动，甚至一名患有预激综合征和室上性阵发性心动过速的患者以及5名室性心动过速患者中的1名所取得的优异结果表明了该治疗的抗心律失常有效性。一般来说，治疗以每天240毫克的剂量持续口服，并且能够控制临床情况且无副作用。
